{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:57Z","timestamp":1794047397198,"version":"4.8.0"},"reference-count":62,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from lymphoblasts of T-cell origin. While TALL accounts for only 15% of childhood and 25% of adult ALL, 30% of patients relapse with a poor outcome. Targeted therapy of resistant and high-risk pediatric T-ALL is therefore urgently needed, together with precision medicine tools allowing the testing of efficacy in patient samples. Furthermore, leukemic cell heterogeneity requires drug response assessment at the single-cell level. Here we used single-cell mass cytometry to study signal transduction pathways such as JAK-STAT, PI3K-AKT-mTOR and MEK-ERK in 16 diagnostic and five relapsed T-ALL primary samples, and investigated the in vitro response of cells to Interleukin-7 (IL-7) and the inhibitor BEZ-235. T-ALL cells showed upregulated activity of the PI3K-AKT-mTOR and MEK-ERK pathways and increased expression of proliferation and translation markers. We found that perturbation induced by the ex vivo administration of either IL-7 or BEZ-235 reveals a high degree of exclusivity with respect to the phospho-protein responsiveness to these agents. Notably, these response signatures were maintained from diagnosis to relapse in individual patients. In conclusion, we demonstrated the power of mass cytometry single-cell profiling of signal transduction pathways in T-ALL. Taking advantage of this advanced approach, we were able to identify distinct clusters with different responsiveness to IL-7 and BEZ-235 that can persist at relapse. Collectively our observations can contribute to a better understanding of the complex signaling network governing T-ALL behavior and its correlation with influence on the response to therapy.<\/jats:p>","DOI":"10.3324\/haematol.2021.278796","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T03:29:53Z","timestamp":1634786993000},"page":"1293-1310","source":"Crossref","is-referenced-by-count":21,"title":["Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of &lt;i&gt;ex vivo&lt;\/i&gt; treated pediatric T-cell acute lymphoblastic leukemia cells"],"prefix":"10.3324","volume":"107","author":[{"given":"Daniela","family":"Kuzilkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bugarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Rejlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel R.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik E.","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Paganin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gaipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"36482","doi-asserted-by":"crossref","unstructured":"Pui CH. Acute lymphoblastic leukemia: introduction. Semin Hematol. 2009; 46(1):1-2.","DOI":"10.1053\/j.seminhematol.2008.09.011"},{"key":"36483","doi-asserted-by":"crossref","unstructured":"Girardi T, Vicente C, Cools J, Keersmaecker K De. The genetics and molecular biology of T-ALL. Blood. 2017; 129(9):1113-1123.","DOI":"10.1182\/blood-2016-10-706465"},{"key":"36484","doi-asserted-by":"crossref","unstructured":"Klumper E, Pieters R, Veerman A. In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia. Blood. 1995; 86(10):3861-3868.","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861"},{"key":"36485","unstructured":"Gao J, Liu WJ. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018; 22(22):7858-7866."},{"key":"36486","doi-asserted-by":"crossref","unstructured":"Lauten M, Moricke A, Beier R. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012; 97(7):1048-1056.","DOI":"10.3324\/haematol.2011.047613"},{"key":"36487","doi-asserted-by":"crossref","unstructured":"Follini E, Marchesini M, Roti G. Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2019; 20(12):3021.","DOI":"10.3390\/ijms20123021"},{"key":"36488","doi-asserted-by":"crossref","unstructured":"Scheijen B. Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies. Cancer Drug Resist. 2019; 2:647-664.","DOI":"10.20517\/cdr.2019.29"},{"key":"36489","doi-asserted-by":"crossref","unstructured":"De Smedt R, Morscio J, Goossens S, Van Vlierberghe P. Targeting steroid resistance in T-cell acute lymphoblastic leukemia. Blood Rev. 2019; 38:100591.","DOI":"10.1016\/j.blre.2019.100591"},{"key":"36490","doi-asserted-by":"crossref","unstructured":"Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med. 1993; 177(2):305-316.","DOI":"10.1084\/jem.177.2.305"},{"key":"36491","doi-asserted-by":"crossref","unstructured":"Lindqvist CM, Lundmark A, Nordlund J. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget. 2016; 7(39):64071-64088.","DOI":"10.18632\/oncotarget.11773"},{"key":"36492","doi-asserted-by":"crossref","unstructured":"Abraham N, Ma MC, Snow JW, Miners MJ, Herndier BG, Goldsmith MA. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene. 2005; 24(33):5252-5257.","DOI":"10.1038\/sj.onc.1208726"},{"key":"36493","doi-asserted-by":"crossref","unstructured":"Silva A, Laranjeira ABA, Martins LR. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011; 71(14):4780-4789.","DOI":"10.1158\/0008-5472.CAN-10-3606"},{"key":"36494","doi-asserted-by":"crossref","unstructured":"Dibirdik I, Langlie M, Ledbetter J. Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. Blood. 1991; 78(3):564-570.","DOI":"10.1182\/blood.V78.3.564.564"},{"key":"36495","doi-asserted-by":"crossref","unstructured":"Treanor LM, Zhou S, Janke L. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med. 2014; 211(4):701-713.","DOI":"10.1084\/jem.20122727"},{"key":"36496","doi-asserted-by":"crossref","unstructured":"Ribeiro D, Mel\u00e3o A, van Boxtel R. STAT5 is essential for IL-7\u2013mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2018; 2(17):2199-2213.","DOI":"10.1182\/bloodadvances.2018021063"},{"key":"36497","doi-asserted-by":"crossref","unstructured":"Shochat C, Tal N, Bandapalli OR. Gain-of-function mutations in interleukin-7 receptor-\u03b1 (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011; 208(5):901-908.","DOI":"10.1084\/jem.20110580"},{"key":"36498","doi-asserted-by":"crossref","unstructured":"Zenatti PP, Ribeiro D, Li W. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011; 43(10):932-939.","DOI":"10.1038\/ng.924"},{"key":"36499","doi-asserted-by":"crossref","unstructured":"Cant\u00e9-Barrett K, Spijkers-Hagelstein JAP, Buijs-Gladdines JGCAM. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia. 2016; 30(9):1832-1843.","DOI":"10.1038\/leu.2016.83"},{"key":"36500","doi-asserted-by":"crossref","unstructured":"Li Y, Buijs-Gladdines JGCAM, Cant\u00e9-Barrett K. IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med. 2016; 13(12):e1002200.","DOI":"10.1371\/journal.pmed.1002200"},{"key":"36501","doi-asserted-by":"crossref","unstructured":"Oliveira ML, Akkapeddi P, Alcobia I. From the outside, from within: biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia. Cell Signal. 2017; 38:10-25.","DOI":"10.1016\/j.cellsig.2017.06.011"},{"key":"36502","doi-asserted-by":"crossref","unstructured":"Kim R, Boissel N, Touzart A. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia. 2020; 34(7):1730-1740.","DOI":"10.1038\/s41375-019-0685-4"},{"key":"36503","doi-asserted-by":"crossref","unstructured":"Liu Y, Easton J, Shao Y. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017; 49(8):1211-1218.","DOI":"10.1038\/ng.3909"},{"key":"36504","doi-asserted-by":"crossref","unstructured":"Goossens S, Radaelli E, Blanchet O. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun. 2015; 6(1):5794.","DOI":"10.1038\/ncomms6794"},{"key":"36505","doi-asserted-by":"crossref","unstructured":"Zhang J, Ding L, Holmfeldt L. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-163.","DOI":"10.1038\/nature10725"},{"key":"36506","doi-asserted-by":"crossref","unstructured":"Vicente C, Schwab C, Broux M. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica. 2015; 100(10):1301-1310.","DOI":"10.3324\/haematol.2015.130179"},{"key":"36507","doi-asserted-by":"crossref","unstructured":"Meyer LK, Huang BJ, Delgado-Martin C. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020; 130(2):863-876.","DOI":"10.1172\/JCI130189"},{"key":"36508","doi-asserted-by":"crossref","unstructured":"Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003; 3(4):317-330.","DOI":"10.1038\/nri1056"},{"key":"36509","doi-asserted-by":"crossref","unstructured":"Mendes RD, Sarmento LM, Cant\u00e9-Barrett K. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. Blood. 2014; 124(4):567-578.","DOI":"10.1182\/blood-2014-03-562751"},{"key":"36510","doi-asserted-by":"crossref","unstructured":"Milella M, Falcone I, Conciatori F. PTEN: multiple functions in human malignant tumors. Front Oncol. 2015; 5:24.","DOI":"10.3389\/fonc.2015.00024"},{"key":"36511","doi-asserted-by":"crossref","unstructured":"Zuurbier L, Petricoin EF, Vuerhard MJ. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012; 97(9):1405-1413.","DOI":"10.3324\/haematol.2011.059030"},{"key":"36512","doi-asserted-by":"crossref","unstructured":"Homminga I, Pieters R, Langerak AW. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011; 19(4):484-497.","DOI":"10.1016\/j.ccr.2011.02.008"},{"key":"36513","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002; 1(1):75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"36514","doi-asserted-by":"crossref","unstructured":"Soulier J, Clappier E, Cayuela JM. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005; 106(1):274-286.","DOI":"10.1182\/blood-2004-10-3900"},{"key":"36515","doi-asserted-by":"crossref","unstructured":"Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL. The biology of relapsed acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2014; 36(6):413-418.","DOI":"10.1097\/MPH.0000000000000179"},{"key":"36516","doi-asserted-by":"crossref","unstructured":"Loosveld M, Castellano R, Gon S. Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia (T-ALL). Oncotarget. 2014; 5(10):3168-3172.","DOI":"10.18632\/oncotarget.1873"},{"key":"36517","doi-asserted-by":"crossref","unstructured":"Bodenmiller B, Zunder ER, Finck R. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012; 30(9):858-867.","DOI":"10.1038\/nbt.2317"},{"key":"36518","doi-asserted-by":"crossref","unstructured":"Bendall SC, Simonds EF, Qiu P. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011; 332(6030):687-696.","DOI":"10.1126\/science.1198704"},{"key":"36519","doi-asserted-by":"crossref","unstructured":"Bonaccorso P, Bugarin C, Buracchi C. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: impact of PTEN exon 7 mutation on PI3K\/Akt and JAK\u2013STAT signaling pathways. Cytometry B Clin Cytom. 2020; 98(6):491-503.","DOI":"10.1002\/cyto.b.21882"},{"key":"36520","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Buldini B, Gaipa G. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018; 94(1):82-93.","DOI":"10.1002\/cyto.b.21518"},{"key":"36521","doi-asserted-by":"crossref","unstructured":"Watson M, Chow S, Barsyte D. The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytoametry. Cytometry A. 2014; 85(1):78-87.","DOI":"10.1002\/cyto.a.22344"},{"key":"36522","doi-asserted-by":"crossref","unstructured":"Mei HE, Leipold MD, Maecker HT. Platinum-conjugated antibodies for application in mass cytometry. Cytometry A. 2016; 89(3):292-300.","DOI":"10.1002\/cyto.a.22778"},{"key":"36523","doi-asserted-by":"crossref","unstructured":"Mei HE, Leipold MD, Schulz AR, Chester C, Maecker HT. Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry. J Immunol. 2015; 194(4):2022-2031.","DOI":"10.4049\/jimmunol.1402661"},{"key":"36524","doi-asserted-by":"crossref","unstructured":"Schulz AR, Baumgart S, Schulze J, Urbicht M, Gr\u00fctzkau A, Mei HE. Stabilizing antibody cocktails for mass cytometry. Cytometry A. 2019; 95(8):910-916.","DOI":"10.1002\/cyto.a.23781"},{"key":"36525","doi-asserted-by":"crossref","unstructured":"Chevrier S, Crowell HL, Zanotelli VRT, Engler S, Robinson MD, Bodenmiller B. Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 2018; 6(5):612-620.","DOI":"10.1016\/j.cels.2018.02.010"},{"key":"36526","doi-asserted-by":"crossref","unstructured":"Saeed AI, Sharov V, White J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003; 34(2):374-378.","DOI":"10.2144\/03342mt01"},{"key":"36527","doi-asserted-by":"crossref","unstructured":"Szubert B, Cole JE, Monaco C, Drozdov I. Structure-preserving visualisation of high dimensional single-cell datasets. Sci Rep. 2019; 9(1):8914.","DOI":"10.1038\/s41598-019-45301-0"},{"key":"36528","doi-asserted-by":"crossref","unstructured":"Ding J, Condon A, Shah SP. Interpretable dimensionality reduction of single cell transcriptome data with deep generative models. Nat Commun. 2018; 9(1):2002.","DOI":"10.1038\/s41467-018-04368-5"},{"key":"36529","doi-asserted-by":"crossref","unstructured":"Sulis ML, Williams O, Palomero T. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008; 112(3):733-740.","DOI":"10.1182\/blood-2007-12-130096"},{"key":"36530","doi-asserted-by":"crossref","unstructured":"Silva A, Yunes JA, Cardoso BA. PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008; 118(11):3762-3774.","DOI":"10.1172\/JCI34616"},{"key":"36531","doi-asserted-by":"crossref","unstructured":"Palomero T, Sulis ML, Cortina M. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007; 13(10):1203-1210.","DOI":"10.1038\/nm1636"},{"key":"36532","doi-asserted-by":"crossref","unstructured":"Schrappe M, Valsecchi MG, Bartram CR. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011; 118(8):2077-2084.","DOI":"10.1182\/blood-2011-03-338707"},{"key":"36533","doi-asserted-by":"crossref","unstructured":"Dang C V., O\u2019Donnell KA, Zeller KI, Nguyen T, Osthus RC Li F. The c-Myc target gene network. Semin Cancer Biol. 2006; 16(4):253-264.","DOI":"10.1016\/j.semcancer.2006.07.014"},{"key":"36534","doi-asserted-by":"crossref","unstructured":"Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-990.","DOI":"10.1038\/nrc2231"},{"key":"36535","doi-asserted-by":"crossref","unstructured":"Bonnet M, Loosveld M, Montpellier B. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood. 2011; 117(24):6650-6659.","DOI":"10.1182\/blood-2011-02-336842"},{"key":"36536","doi-asserted-by":"crossref","unstructured":"Piovan E, Yu J, Tosello V. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013; 24(6):766-776.","DOI":"10.1016\/j.ccr.2013.10.022"},{"key":"36537","doi-asserted-by":"crossref","unstructured":"Serafin V, Capuzzo G, Milani G. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood. 2017; 130(25):2750-2761.","DOI":"10.1182\/blood-2017-05-784603"},{"key":"36538","doi-asserted-by":"crossref","unstructured":"Delgado-Martin C, Meyer LK, Huang BJ. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017; 31(12):2568-2576.","DOI":"10.1038\/leu.2017.136"},{"key":"36539","doi-asserted-by":"crossref","unstructured":"Ebinger S, \u00d6zdemir EZ, Ziegenhain C. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016; 30(6):849-862.","DOI":"10.1016\/j.ccell.2016.11.002"},{"key":"36540","doi-asserted-by":"crossref","unstructured":"Martelli AM, Lonetti A, Buontempo F. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv Biol Regul. 2014; 56:6-21.","DOI":"10.1016\/j.jbior.2014.04.004"},{"key":"36541","doi-asserted-by":"crossref","unstructured":"Hall CP, Reynolds CP, Kang MH. Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K\/mTOR inhibitor BEZ235. Clin Cancer Res. 2016; 22(3):621-632.","DOI":"10.1158\/1078-0432.CCR-15-0114"},{"key":"36542","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia indentified in two independent cohorts. Lancet Oncol. 2009; 10(2):147-156.","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"36543","doi-asserted-by":"crossref","unstructured":"Basso G, Veltroni M, Valsecchi MG. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009; 27(31):5168-5174.","DOI":"10.1200\/JCO.2008.20.8934"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278796\/73773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278796\/74525","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10430\/73773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:32Z","timestamp":1794045632000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.278796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.278796","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}